The prognostic value of epidermal growth factor receptor (EGFR) in breast cancer patients. Results of a follow-up study on 149 patients

The expression of epidermal growth factor receptor (EGFR) in breast cancer patients was correlated to the disease-free survival. The study included 149 breast cancer patients. The mean follow-up time was 4.2 years. There was an inverse correlation between EGFR and estrogen receptor (p < 0.003) an...

Full description

Saved in:
Bibliographic Details
Published inActa oncologica Vol. 33; no. 1; p. 13
Main Authors Railo, M J, Smitten, K V, Pekonen, F
Format Journal Article
LanguageEnglish
Published England 1994
Subjects
Adult
Aged
Breast Neoplasms - pathology
ErbB Receptors - metabolism
Female
Follow-Up Studies
Humans
Lymphatic Metastasis
Middle Aged
Prognosis
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Regression Analysis
Online AccessGet more information

Cover

More Information
Summary:The expression of epidermal growth factor receptor (EGFR) in breast cancer patients was correlated to the disease-free survival. The study included 149 breast cancer patients. The mean follow-up time was 4.2 years. There was an inverse correlation between EGFR and estrogen receptor (p < 0.003) and progesterone receptor (p < 0.013). Subdivision of EGFR showed that patients with EGFR > or = 0.60%, regarded as EGFR positive, had a worse prognosis than patients with EGFR binding < 0.60%, regarded as EGFR negative (p = 0.004). In the ER negative group, EGFR positive patients had a shorter relapse-free time than patients with EGFR negative cancer (p < 0.009). The same subdivision among ER positive patients showed no statistically significant difference.
ISSN:0284-186X
DOI:10.3109/02841869409098368